


First-in-class antibiotic is safe in rats

PERTH, WESTERN AUSTRALIA, AUSTRALIA, January 17, 2019 /EINPresswire.com/ -- A scientific paper published in the journal, [Scientific Reports](#), has shown Ramizol® a first-in-class stilbene-based investigational antibiotic for the treatment of CDI is safe in rats. The objective of the study was to evaluate the potential general toxicity in male and female rats that may arise from repeated exposure of Ramizol® for 14 days at doses of 50 mg/kg, 500 mg/kg and 1500 mg/kg administered orally.

The research, which was undertaken jointly by [Boulos & Cooper Pharmaceuticals](#), US-based Product Safety Labs and ToxStrategies Inc., and Flinders University, has shown no mortalities in this study and no-Ramizol®-related clinical observations or side-effects. Additionally, there were no changes in mean body weight, body weight gain, food consumption or food efficiency in male and female rats attributed to the intake of the drug.

Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said "We are extremely pleased with these results for two reasons. Firstly, we were able to dose rats at a very high dose, equivalent to 150 mg/mL. This level of solubility provides Ramizol® with an edge over its competition where solubility does not limit the need to administer high doses to target drug resistant bacteria. Secondly, the high level of tolerance of Ramizol® in rats has de-risked the development of this asset significantly for our first-in-man clinical trials and has given us the confidence to pursue its development".

Ramiz Boulos
Boulos & Cooper Pharmaceuticals Pty Ltd
+61 431 150 538
[email us here](#)
Visit us on social media:
[LinkedIn](#)



boulos&cooper
PHARMACEUTICALS

First-in-class antibiotic is safe in rats

A scientific paper published in the journal, *Scientific Reports*, has shown Ramizol®, a first-in-class stilbene-based investigational antibiotic for the treatment of CDI is safe in rats. The objective of the study was to evaluate the potential general toxicity in male and female rats that may arise from repeated exposure of Ramizol® for 14 days at doses of 50 mg/kg, 500 mg/kg and 1,500 mg/kg administered orally.

The research, which was undertaken jointly by Boulos & Cooper Pharmaceuticals, US-based Product Safety Labs and ToxStrategies Inc., and Flinders University, has shown no mortalities in this study and no Ramizol®-related clinical observations or side-effects. Additionally, there were no changes in mean body weight, body weight gain, food consumption or food efficiency in male and female rats attributed to the intake of the drug.

Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said "We are extremely pleased with these results for two reasons. Firstly, we were able to dose rats at a very high dose, equivalent to 150 mg/mL. This level of solubility provides Ramizol® with an edge over its competition where solubility does not limit the need to administer high doses to target drug-resistant bacteria. Secondly, the high level of tolerance of Ramizol® in rats has de-risked the development of this asset significantly for our first-in-man clinical trials and has given us the confidence to pursue its development".

Download the paper here:
<http://www.nature.com/articles/s41598-018-36690-9>

For further information, please contact:
Dr Ramiz Boulos
Chief Executive Officer
email: ceo@bouloscooper.com
telephone: +61 431 150 538

website: www.bouloscooper.com
email: info@bouloscooper.com

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.